Peri-operative acute kidney injury is common, accounting for 30-40% of all in-hospital cases of acute kidney injury. It is associated with clinically significant morbidity and mortality even with what was hitherto regarded as relatively trivial increases in serum creatinine, and carries over a 12-fold relative risk of death following major abdominal surgery. Comorbid conditions such as diabetes, hypertension, liver disease and particularly pre-existing chronic kidney disease, as well as the type and urgency of surgery, are major risk factors for the development of postoperative acute kidney injury. As yet, there are no specific treatment options for the injured kidney, although there are several modifiable risk factors of which the anaesthetist should be aware. As well as the avoidance of potential nephrotoxins and appropriate volume balance, optimal anaesthetic management should aim to reduce the risk of postoperative renal complications. This may include careful ventilatory management and blood pressure control, as well as appropriate analgesic strategies. The choice of anaesthetic agent may also influence renal outcomes. Rather than concentrate on the classical management of acute kidney injury, this review focuses on the potential development of acute kidney injury peri-operatively, and the means by which this may be ameliorated.
Introduction
Some of the earliest observations of the effects of anaesthesia on renal function were made over a century ago [1, 2] . Initial reports described the effects of ether anaesthesia where, following induction, a marked increase in both urine output and non-protein nitrogen excretion was noted. However, after 90 min of anaesthesia, both parameters had decreased to just 3.6% and 2.2% of baseline, respectively. At 24 h postoperatively, recovery to 43% and 84% of baseline was observed, with earlier recovery of secretory rather than nitrogenous excretory function. The authors concluded that "We cannot but think that in cases of prolonged ether anaesthesia, this inhibition of renal activity must exercise a most injurious effect on the general metabolism and condition of the patient" [2] . Although both anaesthetic agents and techniques have evolved since 1905, the potentially deleterious effects of anaesthesia on renal function remain. Historically, the comparison of studies investigating kidney impairment, particularly in the acute setting, was complicated by the heterogeneity in defining 'acute renal failure', but this problem was addressed with the introduction of the concept of acute kidney injury (AKI) [3] . The development of AKI, as defined by observed changes in serum creatinine (SCr) and/or urine output, is now known to be a significant cause of both morbidity and mortality, and when severe enough to require renal replacement therapy (RRT), the observed mortality approaches 46% [4, 5] . The subsequent definitions of AKI proposed by the Kidney Disease Improving Global Outcomes (KDIGO) group in 2011 provided greater clarity, and are now generally accepted as the standard definitions of AKI (Table 1 ) [6] .
Acute kidney injury may complicate up to 20% of all hospital admissions and is recognised as a major complication of surgery, with approximately 30-40% of cases of hospital-acquired AKI occurring in the perioperative setting [7, 8] . Moreover, the development of AKI in the peri-operative period is associated with increased risks of sepsis, coagulopathy and prolonged mechanical ventilation [9] . The incidence of AKI postoperatively depends in part on the surgery, but in a large US study, postoperative AKI occurred in 11.8% of 161,185 patients who underwent major surgery [10] . Of these, 76% were AKI stage 1, 15% stage 2 and 9% stage 3, of whom approximately 35% required RRT. As well as being a relatively common occurrence, the development of postoperative AKI translates into a significant mortality risk. For example, Kheterpal et al. described an eight-fold increase in mortality in patients with perioperative AKI [11] . Furthermore, a recent systematic review, describing AKI outcomes in 82,514 patients undergoing abdominal surgery, found a pooled incidence of AKI of 13.4% (95%CI 10.9-16.4%), with a 12.6-fold relative risk of death in the presence of postoperative AKI (95%CI 6.8-23.4) [12] . Non-renal postoperative complications were also more frequent, and lengths of stay longer in patients with AKI. Not only is mortality higher in patients with peri-operative AKI, but even after apparent complete renal recovery, patients who developed AKI are at increased risk of developing chronic kidney disease (CKD) and end-stage renal disease (ESRD) [13] .
Who is at risk of renal complications?
Many factors influence the potential development of renal complications in the peri-operative period. Despite the heterogeneity in terms of potential pathophysiology, there is a degree of consistency across surgical specialties with regard to risk factors for AKI, as outlined in Table 2 . Common risk factors include the presence of vascular disease, CKD, hypertension, cardiac failure and diabetes, all of which are strongly associated with postoperative AKI [14] . However, the incidence of AKI is also procedurally related. Cardiovascular surgery, for example, has been extensively studied with regard to postoperative AKI, and incidence rates as high as 30% have been reported [9] . Cardiopulmonary bypass is a particular contributor and is associated with many potentially injurious insults to the kidney, including ischaemia-reperfusion injury, micro-embolic phenomena, decreased renal perfusion pressure and haemodilution [15] . In aortic surgery, mechanical obstruction to blood flow can occur during arterial cross-clamping, though more transient obstruction to venous or arterial flow may be seen with other abdominal surgeries. Non-renal organ transplant surgery also carries a significant risk of postoperative AKI. In orthotopic liver transplantation, for example, AKI rates of 25-60% have been observed, and in a single-centre study, AKI occurred in 50% of patients, and was associated with a reduction in 90-day survival of nearly 9% [16] . Intraperitoneal surgery in general, and particularly small bowel resection, is also associated with increased risk of postoperative AKI [11, 17] . Although laparoscopic techniques in general are associated with a lower risk of postoperative AKI, pneumoperitoneum still carries a risk of renal injury, with high insufflation pressures associated with oliguria, and with anuria being induced at around 30 mmHg. This is not only because of the effects on central venous vasculature, but also due to renal parenchymal compression [18] . The timing of surgery also plays a role, with emergent surgery carrying the greatest risk of postoperative AKI [11, 17] . The degree of intra-operative blood loss has also been associated with increased postoperative AKI, as has red cell transfusion [19] . Moreover, patients who are bleeding may have been exposed to potential nephrotoxins such as intravascular contrast agents, which may also contribute to the development of AKI; however, the risk of contrast-associated AKI should not delay diagnostic imaging [20] .
Minimising the risk of renal complications of anaesthesia
Much is published about the anaesthetic management of patients with existing renal impairment, and a thorough pre-operative assessment should alert the anaesthetist to the presence of CKD, or indeed the presence of AKI. Subsequent measures should be taken to minimise risks or potential complications resulting from the patients' altered pharmacodynamics, potential for drug interaction(s) and comorbidities. The pathophysiology of postoperative AKI is diverse, with considerable interactions; less commonly discussed are renal complications relating directly or indirectly to anaesthesia. This may be related to a single cause but is more likely to be multifactorial in nature (Fig. 1) . The potential to ameliorate renal injury will depend on the nature of the insult, together with the potential risk factors, which may either be fixed or modifiable.
Non-modifiable risk factors
Some risk factors are fixed and offer little in terms of modifiable actions, particularly acutely; these include age, the presence of CKD, cardiovascular comorbidities and obesity. As discussed, the incidence of postoperative AKI varies considerably depending on the type of surgery, and there are increasing data available regarding AKI in non-cardiac surgery settings [21] . A retrospective analysis of over 160,000 patients in the United States with AKI defined by KDIGO criteria demonstrated unadjusted incidences of AKI ranging from 4.1% for ear, nose and throat (ENT) surgery to 18.7% for cardiac surgery [10] . Relative risks (RR) for the development of AKI using general surgical patients as . This is in keeping with other previously reported studies [8, 11] . Although risk scoring systems have been devised to aid in identifying surgical patients at highest risk, outside of cardiac surgery these perform poorly, as risk stratification has been hampered by variable definitions of AKI and inconsistent outcomes [14] . A recent systematic review of risk prediction models following non-cardiac surgery found currently available models lacked external validation and robust impact analyses, and recommended that further data were needed before clinical use could be recommended [22] .
Modifiable risk factors
Although the treatment of established AKI is, at present, principally supportive in nature, there are several strategies that may be adopted which have the potential to minimise renal complications [20] . These are summarised in Fig. 2 .
The pre-operative approach
The pre-operative visit offers the anaesthetist a chance to intervene to mitigate the risk of developing postoperative AKI. Minimising fasting is known to be beneficial, as fasting induces metabolic stress, and impairs mitochondrial function and insulin sensitivity, the consequences of which may increase the risk of postoperative AKI [23] . Pre-operative volume resuscitation may be necessary to avoid hypovolaemia-associated kidney injury, and nephrotoxic medications should be stopped where possible. Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) contribute to intra-operative hypotension and reduce glomerular perfusion pressure, and consideration should be given to stopping these on the day of surgery, and their administration should be reviewed regularly postoperatively. However, evidence is lacking for this approach, and the 2014 ACC/AHA guidelines suggest continuing ACE-I peri-operatively. Patients taking b-blockers may be at risk of intra-operative hypotension and bradycardia, and in those with rate-dependent cardiac outputs or other risk factors, consideration may be given to suspending these [24] . The use of non-steroidal anti-inflammatory agents should be balanced against the potential for AKI and the presence of other risk factors, as there is, for example, evidence for an increased incidence of AKI in patients undergoing hip arthroplasty where these agents are used to provide analgesia [25] .
The intra-operative approach

Cardiovascular
Avoiding intra-operative hypotension is paramount, as hypotension is an independent risk factor for postoperative AKI through renal hypoperfusion and subsequent reduction in medullary blood flow. Most patients with postoperative AKI have had an episode of peri-operative haemodynamic instability at some stage [26] . A retrospective study of over 33,000 patients examining the association between intraoperative mean arterial pressure (MAP), postoperative AKI and myocardial injury, found an incidence of postoperative AKI of 7.4%. The cut-off MAP for increasing risk of postoperative AKI and myocardial injury was 55 mmHg. Unsurprisingly, the AKI risk increased with the duration of MAP < 55 mmHg, with a period of hypotension of over 20 min having a relative risk of 1.51 (95%CI 1.24-1.84) [27] [28] [29] . Increased mortality was demonstrated with ≥ 20 min of MAP less than 55 mmHg, but no interaction with the pre-operative MAP was noted, suggesting that absolute, not relative, MAP values could be used. In addition, prolonged periods of MAP ≤ 65 mmHg may increase postoperative AKI risk. The association between AKI and intra-operative hypotension appears to be a consistent finding [28, 29] . While the MAP is important, low diastolic arterial perfusion pressures that activate the renin-angiotensin-aldosterone system and increase anti-diuretic hormone levels are also related to the progression of AKI in cardiac surgery patients [30] .
In addition to minimising anaesthesia-related hypotension through appropriate anaesthetic agent use, therapeutic options for the treatment of hypotension continue to be either fluids or vasopressors or inotropes. Goal-directed fluid therapy should probably be considered in patients at high risk of developing postoperative AKI and in patients undergoing high-risk surgery, although the literature is not clear. A metaanalysis of haemodynamic optimisation found both Figure 2 Peri-operative modifiable risk factors for developing acute kidney injury. NSAIDS, non-steroidal antiinflammatory drugs; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; PPI, proton pump inhibitors; H2A, Histamine type-2 receptor antagonists; MH, malignant hyperpyrexia, V T , tidal volume; PEEP, positive end-expiratory pressure; MAP, mean arterial pressure; GDFT, goal-directed fluid therapy.
AKI and mortality were reduced when using fluid optimisation with inotropes [31] . However, a recent post-hoc analysis of the POM-O randomised controlled trial found that the use of intra-operative noradrenaline and persistent lactataemia were associated with postoperative creatinine rises, whereas goal-directed therapy did not prevent AKI [32] . One advantage of goal-directed fluid therapy is the avoidance of volume overload, as this is associated with both increased AKI and mortality, while more appropriately timed fluid is associated with reduced AKI and use of inotropic agents [33] . Given the impact of hypotension on postoperative AKI, the judicious use of vasopressors to counteract intra-operative hypotension is appropriate. Noradrenaline has been shown to improve renal blood flow, glomerular filtration rate and urine output. Vasopressin may have some potential benefit over noradrenaline, but definitive outcome benefits have not been shown. Low-dose dopamine is no longer considered to be reno-protective and is not recommended for the treatment of AKI [20] .
Respiratory
Reduction in renal function with 'pressure-breathing' in healthy volunteers was noted 70 years ago, with reduced function continuing for several hours following cessation of ventilation [34] . More recently, the multifactorial nature of the effects of mechanical ventilation of the lungs on renal function has been described, with the detrimental effects of hypercapnoea, hypoxia and cardiac output noted. Indeed, a recent systematic review found that mechanical ventilation was associated with a three-fold increase in the odds of developing AKI. However, there was a high degree of heterogeneity in the included trials, and further work is necessary to elucidate specific strategies to minimise the postoperative AKI risk from ventilation [35] . In animal models, the impact of ventilation appeared greatest in the presence of generalised sepsis, and protective ventilation may be helpful even in the absence of any acute lung injury (ALI) [36] . A pragmatic approach in high-risk surgical patients would be to adopt low tidal volume ventilation settings of 5-7 ml.kg
À1
, using optimal PEEP settings as determined by oxygenation and compliance, together with the avoidance of hypoxia and hypercarbia.
Vascular
Although not a direct result of anaesthesia, cholesterol embolisation syndrome is an under-recognised cause of AKI. Embolisation may occur spontaneously, but is more common during interventions that disrupt the plaque surface, such as arteriography and vascular surgery, and results in ischaemic end-organ damage through a combination of mechanical plugging and inflammation in the target arteries. Risk factors are similar to AKI and include male sex, hypertension, smoking, hypercholesterolaemia, diabetes and aortic aneurysm [37] . Classically characterised by a triad of renal failure, livedo reticularis and eosinophilia, it can also present atypically with fever, myalgia and multiorgan derangement [38] . Estimates of the incidence of cholesterol embolisation syndrome resulting from vascular procedures have ranged from 0.15% in clinical studies to 25-30% in autopsy series [39] . This probably means that cholesterol embolisation syndrome occurs in a subtle form following intravascular procedures more often than is picked up by clinical presentation [40] . There is no specific treatment for cholesterol embolisation syndrome, with supportive measures including modifications of risk factors, statins and antiplatelet agents together with utilisation of surgical and endovascular techniques to reduce sources of cholesterol emboli.
Anaesthetic technique
There are limited data comparing regional (RA) and general anaesthesia (GA) in terms of renal protection. In a retrospective study of open abdominal aortic surgery patients, those given intrathecal morphine developed less AKI than those given systemic analgesia or those treated with thoracic epidurals, although confounding factors included disparity in volume and pressor usage [41] . Subsequent studies in endovascular aneurysm repair did not replicate any beneficial effect of RA over GA for preventing postoperative AKI [17] . The largest study to date is a matched analysis of over 260,000 GA cases and over 64,000 RA cases on the National Surgical Quality Improvement Program (NSQIP) database [42] . No beneficial effect of one anaesthetic technique over another regarding the development of renal complications was noted, despite RA being associated with significant benefits in terms of other peri-operative complications. Interestingly, the first non-flammable halogenated volatile anaesthetic, methoxyflurane, was associated with significant nephrotoxicity through inorganic fluoride formation [43] . However, it is now accepted that not only is sevoflurane clinically not nephrotoxic, volatile anaesthetics exhibit multi-organ protective effects following ischaemic or inflammatory injury in the peri-operative period. Moreover, pre-treatment with volatile agents appears to be protective through so-called anaesthetic preconditioning [44] . In terms of biological plausibility, volatile anaesthetics are known to activate several pathways involved in production of cytoprotective and anti-inflammatory signalling molecules, which may reduce renal ischaemia-reperfusion injury seen in surgical procedures such as organ transplant, cardiac and vascular surgery [45] . To date, the evidence that volatile anaesthetics provide renal protection is somewhat mixed. A recent systematic review of patients undergoing cardiac surgery suggested benefit, but the studies were confounded by a lack of homogeneity in AKI reporting; although a positive effect on postoperative serum creatinine was observed, there was no effect on hard end points such as RRT [46] .
Glycaemic control
Although the use of intensive insulin therapy to achieve tight control of glucose levels has fallen from favour given safety concerns, there is certainly evidence that hyperglycaemia may increase the risk of postoperative AKI [47] . Increasingly, evidence seems to suggest that glycaemic variability is an independent variable for both AKI and mortality in a variety of clinical settings, including cardiac surgery [48] . Given these data, it would seem prudent to avoid sustained hyperglycaemia and avoid rapid alterations in blood sugar through regular monitoring in high-risk groups.
Musculoskeletal
Muscle injury leading to AKI through rhabdomyolysis classically results from trauma such as following crush injury, but may also complicate prolonged immobilisation or compartment syndrome [49] . Other causes include both prescribed and illicit drugs, and rarer causes such as malignant hyperpyrexia and congenital susceptibilities. The breakdown of striated muscle ultimately progressing to myocyte necrosis causes AKI in approaching 50% of patients with rhabdomyolysis through renal vasoconstriction, intraluminal cast formation and direct cytotoxicity, induced by haem protein [50] . Anaesthesia masks the pain and paraesthesia of prolonged muscle compression that would alert the conscious patient, and rhabdomyolysis has been reported in patients undergoing surgical procedures in whom pressure necrosis of muscle occurs from positioning. Lengthy procedures (> 4 h) and high BMI, together with hypotensive anaesthesia, are significant risk factors, and tourniquet use has also been associated with rhabdomyolysis. Prompt detection and management may reduce the severity of the insult, but require a high index of suspicion; prompt volume resuscitation is the mainstay of treatment, along with identification and reversal of the underlying cause of muscle injury. This may include: stopping potentially harmful drugs; patient temperature control; and treatment of infection. Various intravenous fluids have been used to treat rhabdomyolysis, but no randomised controlled trials have demonstrated superiority of one regime over another. Although RRT is used to treat established AKI secondary to rhabdomyolysis, there is scant evidence to suggest improved outcomes in preventing rhabdomyolysis-induced AKI over and above conventional treatment. In part, this reflects the poor methodological quality of reported studies and lack of data relating to clinically important outcomes [51] .
The postoperative approach
The immediate postoperative management of patients at significant risk of postoperative AKI follows the same principles as outlined above, namely preservation of renal perfusion pressure, appropriate volume resuscitation and avoidance of potential nephrotoxins. Consideration should be given to utilising level-1 or -2 postoperative care facilities where appropriate, as close monitoring and early treatment may help prevent progression of AKI, given that several postoperative complications are associated with renal dysfunction [52] . The effects of postoperative haemorrhage, sepsis, and acute cardiac dysfunction should be mitigated through prompt diagnosis and management, and recognition of rhabdomyolysis and intra-abdominal hypertension will improve outcomes. Renal tract imaging should be considered for those in whom obstruction may be a contributing factor to AKI. Where severe AKI develops, then management should be targeted towards minimising the acute sequelae, such as metabolic acidosis, symptomatic uraemia and hyperkalaemia, and where necessary, this may require RRT. Given that AKI is defined through changes in serum creatinine and urine output, it must also be remembered that postoperative oliguria may be a normal physiological response and may be due to salt and water retention reflecting a degree of hypovolaemia. However, similar neuroendocrine responses following pain, trauma and surgery may result in oliguria in the absence of haemodynamic compromise. Under such circumstances, over-zealous fluid administration may be harmful [14] .
Future considerations
Identification of the peri-operative patient at risk of AKI is relatively straightforward, given the established risk factors that have been identified. However, defining AKI can be difficult if a premorbid serum creatinine is unavailable, as may be the case in emergency situations, and may be recognised late after the perioperative insult. Both serum creatinine concentration and urine output are functional markers of renal status, not direct markers of kidney injury. Indeed, serum creatinine is a delayed and insensitive biomarker of changes in kidney function and is affected by many factors [53] . Patients with reduced muscle mass, for example, may not have a robust rise in serum creatinine, despite substantial kidney injury, and in individuals with normal premorbid renal function, the serum creatinine may never rise to levels considered pathological. This 'subclinical AKI' also carries significant short-and long-term risks. However, over the last few years, much effort has been directed at discovering candidate molecules which can improve the early detection of AKI, as well as potentially assist in differential diagnosis and enhanced patient management [54] . These new biomarkers of AKI have the ability to identify injury to the tubular system, and as a consequence identify patients who are going to develop AKI [55] . A number of novel potential biomarkers that are measurable in the urine or plasma of patients with AKI have been identified, including neutrophil gelatinase-associated lipocalin, kidney injury molecule 1 (KIM-1), interleukin 18, liver-type fatty acid-binding protein (L-FABP), tissue inhibitor of metalloproteinase 2 (TlMP-2) and insulin-like growth factor binding protein 7 [56] . Although clinical adoption of such biomarkers of AKI is somewhat slow, one may envisage a scenario where biomarker risk stratification becomes an integral part of postoperative care in patients at risk of AKI. This does not help in the operative period, where diagnostic technologies for assessing renal function are limited. However, there are recent advances in the development of real-time glomerular filtration rate monitoring using fluorescent tracers that may provide minute-to-minute assessment of glomerular filtration rate (GFR), and as such provide new insights into the effects of anaesthesia on renal function [57] .
Conclusions
Peri-operative AKI is an important complication with high associated morbidity and mortality. Given that AKI definitions are now standardised, this allows for consistency in both diagnosis and reporting of AKI rates. There are many risk factors for postoperative AKI, some of which are fixed, including the nature and urgency of surgery, age and patient comorbidities. A personalised and multidisciplinary approach to the care of each patient in the peri-operative setting may help to minimise the risk of developing renal complications related to anaesthesia. This may include modifying peri-operative management such as the avoidance of nephrotoxic drugs and hypotension, use of a guided fluid management plan, use of vasopressors or inotropes where required, avoiding high tidal volume ventilation, and avoiding hyperglycaemia or high variability in plasma blood glucose.
